Connect with us

Technology

WCG Announces Research Resilience Solutions to Navigate Institutional Budget Constraints

Published

on

CARY, N.C., April 3, 2025 /PRNewswire/ — WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the release of Research Resilience Solutions, a site optimization initiative and industry-wide thought leadership series aimed at supporting institutions facing significant funding constraints. This new initiative brings together comprehensive site enablement solutions, expertise in clinical trial administration, ethical and biosafety review services, and strategic resilience strategies to help institutions maintain progress and optimize research operations amidst financial constraints. This also aims to engage sites and sponsors in meaningful discussions to support the efficient advancement of clinical research.

By leveraging WCG’s vast experience and tools, institutions can enhance participant enrollment, improve data quality, and accelerate study start-up timelines, ultimately driving research to results faster and more effectively.

“Our goal is to empower research teams to do more in spite of financial constraints, ensuring that important clinical research can thrive even in the face of budget challenges,” said Sam Srivastava, chief executive officer, WCG. “As institutions grapple with reduced funding, we can support them with solutions needed to advance their trials. While doing so, we’ll lead conversations aimed at solving some of our greatest challenges and advancing solutions to drive resiliency in scientific discovery without compromising quality or efficiency.”

WCG’s Research Resilience Solutions enable institutions to:

Increase Trial Volume: Institutions can undertake a greater number of industry-sponsored trials without adding substantial administrative burdens with the support of WCG solutions, thereby maximizing institutional research capabilities.Accelerate Study Start-Up: By improving study start-up timelines with a target of 90 days, institutions can reduce delays and begin trials faster, enhancing overall research productivity.Enhance Enrollment and Data Integrity: Flexible staff augmentation solutions help institutions meet the complexity of participant enrollment in today’s clinical trials while ensuring the integrity and quality of their data, thereby bolstering the impact of their research.Enhance Participant and Public Safety: By leveraging WCG’s industry-leading institutional review board (IRB), institutional biosafety committee (IBC), and data monitoring committee (DMC) solutions, institutions can benefit from streamlined operational efficiencies and ensure appropriate safety and efficacy requirements are met.Optimize Resource Allocation: Institutions can refine their resource allocation to focus on patient-facing activities, reduce the financial burden of research activities, and improve overall financial performance.Build Strategic Resilience Thought Leadership: Research administrators and clinical research leaders will have the opportunity to join the conversation with WCG thought leaders at upcoming executive forums, webinars, workshops, and industry events beginning next week. These collaborative efforts will include sharing best practices and examining real-world stories of institutions that have successfully advanced their research while navigating funding constraints.

“At WCG, we understand the critical role that financial stability plays in the advancement of clinical research, and we know it will take all of us working together to help solve this industry challenge,” said Sandra Smith, senior vice president, Clinical Solutions and Strategic Partnering, WCG. “We’re committed to help institutions navigate these challenges by providing them with the tools, insights, and support they need to continue driving groundbreaking research that brings life-saving treatments to patients sooner.”

By helping institutions build resilience and maintain their research momentum, WCG is committed to fostering a future where financial limitations do not hinder the progress of essential clinical research.

For more information on how WCG can support your institution in navigating financial challenges and optimizing research operations, visit https://www.wcgclinical.com/solutions/site-enablement/.

About WCG

WCG is a global leader of solutions that measurably improve and accelerate clinical research. Biopharmaceutical and medical device companies, contract research organizations (CROs), research institutions, and sites partner with us for our unmatched expertise, data intelligence, and purpose-built technology to make informed decisions and optimize study outcomes, while maintaining the highest standards of human participant protection. WCG raises the bar by pioneering new concepts, reimagining processes, fostering compliance and safety, and empowering those who perform clinical trials to accelerate the delivery of medical therapies and devices that improve lives. For more information, please visit wcgclinical.com or follow us on LinkedIn or X @WCGClinical.

View original content to download multimedia:https://www.prnewswire.com/news-releases/wcg-announces-research-resilience-solutions-to-navigate-institutional-budget-constraints-302420098.html

SOURCE WCG

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

BOAT ROCKER MEDIA ANNOUNCES FILING OF MANAGEMENT INFORMATION CIRCULAR FOR SPECIAL MEETING OF SHAREHOLDERS

Published

on

By

TORONTO, May 9, 2025 /CNW/ – Boat  Rocker Media Inc. (“BRMI” or the “Company”) (TSX: BRMI) announced today that it has filed its notice of meeting, management information circular and related documents (collectively, the “Meeting Materials”) with securities regulators in connection with the special meeting (the “Meeting”) of the holders (the “Shareholders”) of subordinate voting shares and multiple voting shares of the Company. The Meeting Materials can be accessed either on the Company’s website at www.boatrocker.com or under the Company’s SEDAR+ profile at www.sedarplus.ca.

The Meeting is to be held on June 17, 2025, at 10:00 a.m. (Toronto time) at the offices of Stikeman Elliott LLP, 5300 Commerce Court West, 199 Bay Street, Toronto, Ontario, M5L 1B5, Canada. Only Shareholders whose names have been entered in the register of the Company as at the close of business on April 21, 2025, the record date for the Meeting, or their duly appointed proxyholders, will be entitled to receive notice of and vote at the Meeting or any adjournment(s) or postponement(s) thereof.

At the Meeting, Shareholders will be asked to pass resolutions approving, among things, (i) the reverse take-over of BRMI by Blue Ant Media Inc. (“Blue Ant”), a privately owned company controlled by Michael MacMillan, (ii) the management buyout of Boat Rocker Studios by BRMI Co-Founders and Co-Executive Chairmen, David Fortier and Ivan Schneeberg, and BRMI CEO John Young, and (iii) the sale of the Company’s interests in The Initial Group Global, LLC (“The Initial Group”), a U.S. talent management business, to Fairfax Financial Holdings Limited (collectively, the “Transaction”).

Shareholders are encouraged to vote well in advance of the proxy cut-off time of 10:00 a.m. (Toronto time) on June 13, 2025.

If you have any questions regarding the Transaction or how to vote your shares, please contact the Company’s proxy solicitation agent, Carson Proxy Advisors: (i) by telephone at 1-800-530-5189 (North American toll free); or (ii) by email at info@carsonproxy.com.

About Boat Rocker Media Inc.

Boat Rocker (TSX: BRMI) is the home for creative visionaries. An independent, integrated global entertainment company, BRMI’s purpose is to tell stories and build iconic brands across all genres and mediums. With offices around the world, BRMI’s creative and commercial capabilities include Scripted, Unscripted, and Kids and Family television production, distribution, brand & franchise management, a world-class animation studio, and talent management through a minority stake in The Initial Group, a new company launched by TPG. A selection of BRMI’s projects include: Invasion (Apple TV+), Palm Royale (Apple TV+), Video Nasty (BBC Northern Ireland, BBC Three, Virgin Media One, WDR), This Is the Tom Green Documentary (Prime Video), Orphan Black: Echoes (AMC), American Rust: Broken Justice (Prime Video), Beacon 23 (MGM+), Pretty Baby: Brooke Shields (Hulu), Downey’s Dream Cars (Max), BS High (HBO), Orphan Black (BBC AMERICA, CTV Sci-Fi Channel), Billie Eilish: The World’s a Little Blurry (Apple TV+), The Next Step (BBC, Corus, CBC), Daniel Spellbound (Netflix), and Dino Ranch (Disney+, Disney Junior, CBC). For more information, please visit www.boatrocker.com.

Forward-Looking Information / Cautionary Statements

Certain information contained in this news release may be forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are often, but not always, identified by the use of words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “will”, “may”, “would” and “should” and similar expressions or words suggesting future outcomes. These forward-looking statements reflect material factors and expectations and assumptions of the parties. These forward-looking statements include the assumptions: that the Transaction is able to be completed on the timelines and on the terms currently anticipated; that all regulatory and other required approvals can be obtained on the timelines and in the manner currently anticipated; that the anticipated benefits of the transaction are able to be achieved; that the businesses of both BRMI and Blue Ant will continue to operate in a manner consistent with past practice; and that the parties’ transition plans are effective.

The parties’ estimates, beliefs and assumptions are inherently subject to uncertainties and contingencies regarding future events and, as such, are subject to change. Risks and uncertainties not presently known to the parties or that they presently believe are not material could cause actual results or events to differ materially from those expressed in the forward-looking statements. Additional information on these and other factors that could affect events and results are included in other documents and reports that will be filed by BRMI with applicable securities regulatory authorities and may be accessed through the SEDAR+ website (www.sedarplus.ca). Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the parties’ expectations only as of the date of this press release. The parties disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

U.S. Securities Matters

None of the securities to be issued pursuant to the Transaction have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. The resulting issuer securities to be issued in the Transaction are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

SOURCE Boat Rocker Media Inc.

Continue Reading

Technology

The Secret to Turning Back Time: DermRays Skincare Device Makes Women Look 10 Years Younger

Published

on

By

PLEASANTON, Calif., May 10, 2025 /PRNewswire/ — Every woman dreams of reversing the clock and reclaiming youthful, radiant skin. This Mother’s Day, make that dream a reality with DermRays Skincare Device-the perfect gift for moms and yourself! From May 1-15, enjoy an exclusive $120 OFF during our Mother’s Day Sale. 

DermRays offers two cutting-edge devices tailored to different skincare needs: 

DermRays Revive: Designed for mature skin, this device combats wrinkles, fine lines, and loss of elasticity with advanced 1064nm laser therapy, restoring a lifted, firmer look. DermRays FusionGlow: Ideal for younger users, it tackles acne, dullness, and uneven texture with red and blue light therapy, promoting clearer, glowing skin. DermRays LED: Your daily skincare companion: blue, red, infrared, and mixed light for every need. FDA-cleared safety with built-in eye cups for added protection. Only 15 minutes a day for youthful and radiant skin.

According to the DermRays R&D team, an exciting 1450nm laser skincare device is currently in development and is expected to launch later this year. “We are committed to continuously innovating to meet women’s skincare needs,” says Dr. Yang Lin, dermatology consultant for DermRays. “Our upcoming laser technology will further enhance skin rejuvenation, offering even more transformative results.

“Looking 10 years younger isn’t just a fantasy-it’s achievable with the right technology,” says Dr. Yang Lin, dermatology consultant for DermRays. “Our devices provide salon-quality results at home, making skincare effortless and effective.” 

Don’t miss this limited-time offer! Visit DermRays.com and use code MOTHER120 at checkout. Give the gift of timeless beauty this Mother’s Day-because every woman deserves to feel her best. Stay tuned for the groundbreaking 1450nm laser device and witness how DermRays continues to revolutionize women’s skincare. 

Video – https://www.youtube.com/watch?v=xs7jnzuQX08

 

View original content:https://www.prnewswire.co.uk/news-releases/the-secret-to-turning-back-time-dermrays-skincare-device-makes-women-look-10-years-younger-302449922.html

Continue Reading

Technology

StarCharge Unveils Cutting-Edge BESS Solution at Intersolar 2025

Published

on

By

MUNICH, May 10, 2025 /PRNewswire/ — StarCharge, a global leader in EV charging infrastructure, energy, and digital solutions, has unveiled its latest BESS solution at Intersolar 2025. The launch attracted considerable attention, with a high volume of customers visiting the booth to explore the latest 5MWh BESS solution. Numerous clients showed strong interest and engaged in in-depth consultations, highlighting the market’s enthusiasm for innovative and scalable energy storage solutions.

StarCharge 5MWh Container Energy Storage System

The 5MWh Container Energy Storage System is optimized for utility-scale application, ensuring peak shaving and enhancing grid stability. It features high-performance 314Ah LFP battery cells, BMS, Aerosol Fire Suppression System (FSS) and Environmental Control System, all housed within a 20 feet standardized container. The container is highly corrosion-resistant and complies with global environmental standards, ensuring its resilience in a variety of operating conditions.

Tailored for the European market, the system is well-suited for use as standalone BESS projects, distributed energy storage power stations, industrial and commercial microgrids, EV charging hubs, and renewable energy storage facilities. Its flexible and scalable design addresses the growing demand for reliable energy infrastructure amid Europe’s accelerating transition to renewables and electric mobility.

Future Prospects

Intersolar 2025 marks the international debut for StarCharge 5MWh BESS solution, representing a significant milestone in the company’s global expansion strategy. By leveraging its integrated manufacturing capabilities in ESS containers, battery packs and PCS systems, StarCharge is well-poised to contribute significantly to global energy sustainability efforts.

“As the global energy sector rapidly evolves, StarCharge remains resolutely focused on integrating advanced technologies that support global energy independence,” said a spokesperson for StarCharge. “Our participation at Intersolar 2025 represents a pivotal moment in advancing our strategic initiatives, as we empower businesses, utilities, and communities worldwide with innovative energy solutions.”

About StarCharge

StarCharge, a global leader in EV charging infrastructure and comprehensive energy solutions. It offers a diverse range of intelligent and reliable charging and BESS solutions powered by cutting-edge technology, designed to cater to various scenarios and contribute to building a more efficient and resilient energy future.

For more information, please visit www.starcharge.com or contact BESSinfo@starcharge.com.

View original content:https://www.prnewswire.co.uk/news-releases/starcharge-unveils-cutting-edge-bess-solution-at-intersolar-2025-302451578.html

Continue Reading

Trending